Pier Capital LLC Trims Position in Establishment Labs Holdings Inc. $ESTA

Pier Capital LLC trimmed its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 23.4% during the 4th quarter, HoldingsChannel reports. The firm owned 143,842 shares of the company’s stock after selling 43,837 shares during the quarter. Establishment Labs accounts for about 1.7% of Pier Capital LLC’s investment portfolio, making the stock its 6th largest holding. Pier Capital LLC’s holdings in Establishment Labs were worth $10,483,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Quarry LP bought a new stake in shares of Establishment Labs in the third quarter worth about $34,000. State of Wyoming bought a new stake in shares of Establishment Labs in the third quarter worth about $71,000. Osaic Holdings Inc. increased its holdings in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the last quarter. Truist Financial Corp bought a new stake in shares of Establishment Labs in the fourth quarter worth about $200,000. Finally, Choreo LLC bought a new stake in shares of Establishment Labs in the fourth quarter worth about $204,000. 72.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ESTA. Canaccord Genuity Group lifted their target price on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Needham & Company LLC boosted their price objective on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Mizuho boosted their price objective on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Establishment Labs has an average rating of “Moderate Buy” and a consensus price target of $87.14.

Key Headlines Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q1 revenue beat and strong growth — EST A reported $59.9M in Q1 revenue, up ~44.7% year-over-year and above consensus, showing solid top-line momentum. Earnings Highlights
• Positive Sentiment: FY2026 revenue guidance raised/confirmed — Management set FY2026 revenue guidance of $266.5M–$268.5M, slightly above consensus, supporting growth expectations. Guidance Article
• Positive Sentiment: Minimally invasive segment strength — Company raised its minimally invasive revenue forecast to above $35M, indicating product adoption that could drive higher-margin growth over time. Segment Note
• Positive Sentiment: Analyst uplift — BTIG raised its price target from $88 to $90 and kept a Buy rating, signaling continued analyst confidence in EST A’s growth outlook. BTIG Note
• Neutral Sentiment: Full earnings call transcript and highlights available — Investors can review management’s commentary for color on margin path, product rollout timing and geographic expansion. Call Transcript Earnings Highlights
• Negative Sentiment: EPS miss and continued losses — GAAP EPS of ($0.45) missed consensus (~$0.35 miss) and the company remains unprofitable with negative margins and ROE, raising near-term profitability concerns. Zacks Report
• Negative Sentiment: Profitability and execution risks temper enthusiasm — Despite revenue growth and guidance, investors may be prioritizing the EPS miss, negative net margin (~19%) and high leverage metrics, pressuring the stock. Press Release / Financials

Insider Activity at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 67,249 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $70.78, for a total transaction of $4,759,884.22. Following the transaction, the director owned 1,040,255 shares of the company’s stock, valued at approximately $73,629,248.90. This represents a 6.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 225,000 shares of company stock worth $14,935,438 over the last quarter. Corporate insiders own 9.99% of the company’s stock.

Establishment Labs Trading Down 3.4%

Shares of NASDAQ ESTA opened at $72.03 on Friday. The business’s 50 day moving average is $65.27 and its two-hundred day moving average is $66.59. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs Holdings Inc. has a 1-year low of $33.30 and a 1-year high of $83.31. The stock has a market capitalization of $2.12 billion, a P/E ratio of -48.34 and a beta of 1.12.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The company had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative return on equity of 202.78% and a negative net margin of 19.05%.The company’s revenue was up 44.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.70) earnings per share. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -0.86 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.